<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141061">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672983</url>
  </required_header>
  <id_info>
    <org_study_id>M12-536</org_study_id>
    <nct_id>NCT01672983</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the safety, tolerability, antiviral activity, and
      pharmacokinetics of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in treatment experienced
      Japanese adults with chronic Hepatitis C Virus infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study is intended to examine the potential impact on safety, pharmacokinetics,
      antiviral activity, dose ranging and emergence of resistant variants, of two different doses
      of ABT-450 dosed in combination with ritonavir and ABT-267 for two different treatment
      periods in Pegylated interferon alpha-2a/Ribavirin treatment experienced, Japanese subjects
      with hepatitis C virus genotype 1b and genotype 2 infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assess the percentage of all dosed subjects in each treatment arm with sustained virologic response 24 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation at 24 weeks after the last dose of study drug).</measure>
    <time_frame>Post Treatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects in each treatment arm with treatment-emergent adverse events.</measure>
    <time_frame>Baseline to end of active treatment (up to 24 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the percentage of all dosed subjects in each treatment arm with a sustained virologic response 12 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation 12 weeks after the last dose of study drug).</measure>
    <time_frame>Post Treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the percentage of subjects in each arm with end of treatment response (hepatitis C virus ribonucleic acid less than the lower limit of quantitation).</measure>
    <time_frame>End of Treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with genotype 1b or genotype 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with genotype 1b or genotype 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with genotype 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with genotype 1b</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450</intervention_name>
    <description>ABT-450 (tablet) dosed with ritonavir (capsule)</description>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-267</intervention_name>
    <description>ABT-267 (tablet)</description>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir (capsule)</description>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 1</arm_group_label>
    <arm_group_label>Low dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <arm_group_label>High dose of ABT-450 with ritonavir and ABT-267 for duration 2</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously received Pegylated interferon alpha-2a/Ribavirin.

          -  Chronic hepatitis C virus infection.

          -  Plasma hepatitis C virus ribonucleic acid level  greater than 10,000 International
             Units/milliliter.

          -  Voluntarily sign an informed consent.

        Exclusion Criteria:

          -  History of severe, life-threatening sensitivity to any drug.

          -  Females who are pregnant or plan to become pregnant, or breastfeeding.

          -  Recent history of drug or alcohol abuse.

          -  Positive test result for hepatitis B surface antigen or anti-Human immunodeficiency
             virus antibodies.

          -  Any current or past clinical evidence of cirrhosis.

          -  Previous use of any investigational or commercially available anti-Hepatitis C virus
             agent other than Pegylated interferon alpha-2a and Ribavirin, including previous
             exposure to ABT-450 or ABT-267.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeki  Hashimoto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie GK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 74393</name>
      <address>
        <city>Chuo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 76333</name>
      <address>
        <city>Fukui-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73719</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 76335</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73697</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73700</name>
      <address>
        <city>Inashiki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77253</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73696</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73716</name>
      <address>
        <city>Kurume-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73701</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73714</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75373</name>
      <address>
        <city>Musashino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 81633</name>
      <address>
        <city>Ogaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73698</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73718</name>
      <address>
        <city>Takamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73703</name>
      <address>
        <city>Tanabe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 76327</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73695</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73717</name>
      <address>
        <city>Yufu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese</keyword>
  <keyword>Genotype 1b</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Genotype 2</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
